Capricor Therapeutics (NASDAQ:CAPR) Earns “Overweight” Rating from Cantor Fitzgerald

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $30.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 133.28% from the stock’s previous close.

Separately, HC Wainwright reiterated a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a report on Monday, March 17th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Stock Performance

NASDAQ CAPR opened at $12.86 on Thursday. Capricor Therapeutics has a one year low of $3.52 and a one year high of $23.40. The company has a market capitalization of $584.74 million, a price-to-earnings ratio of -12.13 and a beta of 4.10. The company’s 50-day simple moving average is $14.06 and its two-hundred day simple moving average is $14.55.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.15. The company had revenue of $11.13 million for the quarter, compared to analyst estimates of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. Equities analysts expect that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Summit Investment Advisors Inc. boosted its position in shares of Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Capricor Therapeutics by 172.8% in the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC purchased a new stake in Capricor Therapeutics in the fourth quarter valued at about $68,000. AlphaQuest LLC acquired a new stake in Capricor Therapeutics in the fourth quarter worth about $78,000. Finally, New York State Common Retirement Fund grew its stake in shares of Capricor Therapeutics by 625.0% during the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 5,000 shares during the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.